Overview of Prevention and Intervention Trials for Type 1 Diabetes

Reviews in Endocrine and Metabolic Disorders

Volumn 4, Issue 4, 2003, Pages 317-323

  Daaboul, Jorge ^a   Schatz, Desmond ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Intervention; Prevention; Type 1 diabetes

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; AZATHIOPRINE; B 923; C PEPTIDE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYCLOSPORIN A; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACLIZUMAB; DIAPEP 277; EPRATUZUMAB; ETANERCEPT; GLUCOCORTICOID; GLUTAMATE DEHYDROGENASE; HEAT SHOCK PROTEIN 60; IMMUNOGLOBULIN G ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INSULIN; INSULIN ZINC SUSPENSION; INTERLEUKIN 2 RECEPTOR ANTIBODY; LIGAND; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD20; MONOCLONAL ANTIBODY CD3; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NICOTINAMIDE; PANCREAS ISLET CELL ANTIBODY; RAPAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AUTOIMMUNITY; CANCER RISK; CELL FUNCTION; CLINICAL FEATURE; CLINICAL TRIAL; DIABETES CONTROL; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; GENETIC SUSCEPTIBILITY; GLUCOSE INTOLERANCE; HIGH RISK POPULATION; HUMAN; IMMUNOMODULATION; INFECTION RISK; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; MILK; NEPHROTOXICITY; NONHUMAN; PANCREAS ISLET BETA CELL; PLASMAPHERESIS; REVIEW; SIDE EFFECT; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIOXIDANTS; AUTOANTIGENS; CLINICAL TRIALS; CYTOKINES; DIABETES MELLITUS, TYPE 1; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; INSULIN; NIACINAMIDE;

EID: 0344306547     PISSN: 13899155     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1027308310837     Document Type: Review

References (42)

1. Marcin JP, Glaser N, Barnett P, McCaslin I, Nelson D, Trainor J, Louie J, Kaufman F, Quayle K, Roback M, Malley R, Kuppermann N, American Academy of Pediatrics. The Pediatric Emergency Medicine Collaborative Research Commitee. Factors associated with adverse outcomes in children with diabetic ketoacidosis-related cerebral edema. J Pediatr 2002;141(6):793-797.
2. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329(14):977-986.
3. Sperling M. Diabetes Mellitus. In: Sperling M, ed. Pediatric Endocrinology, 2nd ed. Philadelphia: Saunders, 2002:326.
4. Hogan P, Dall T, Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26(3):917-932.
5. Karvonen M, Viik-Kajander M, Moltchanova E, Libman I, LaPorte R, Tuomilehto J. Incidence of childhood type 1 diabetes world-wide. Diabetes Mondiale (DiaMond) Project Group. Diabetes Care 2000;23(10):1516-1526.
6. Allen C, Palta M, D'Alessio DJ. Risk of diabetes in siblings and other relatives of IDDM subjects. Diabetes 1991;40(7):831-836.
7. Akerblom HK, Vaarala O, Hyoty H, Ilonen J, Knip M. Environmental factors in the etiology of type 1 diabetes. Am J Med Genet 2002;115(1):18-29 (Review).
8. Jun HS, Yoon JW. A new look at viruses in type 1 diabetes. Diabetes Metab Res Rev 2003;19(1):8-31.
9. Foulis AK, Liddle CN, Farquharson MA, Richmond JA, Weir RS. The histopathology of the pancreas in type 1 (insulin-dependent) diabetes mellitus: A 25-year review of deaths in patients under 20 years of age in the United Kingdom. Diabetologia 1986;29(5):267-274.
10. Imagawa A, Hanafusa T, Tamura S, Moriwaki M, Itoh N, Yamamoto K, Iwahashi H, Yamagata K, Waguri M, Nanmo T, Uno S, Nakajima H, Namba M, Kawata S, Miyagawa JI, Matsuzawa Y. Pancreatic biopsy as a procedure for detecting in situ autoimmune phenomena in type 1 diabetes: Close correlation between serological markers and histological evidence of cellular autoimmunity. Diabetes 2001;50(6):1269-1273.
11. Somoza N, Vargas F, Roura-Mir C, Vives-Pi M, Fernandez-Figueras MT, Ariza A, Gomis R, Bragado R, Marti M, Jaraquemada D. Pancreas in recent onset insulin-dependent diabetes mellitus. Changes in HLA, adhesion molecules and autoantigens, restricted T cell receptor V beta usage, and cytokine profile. J Immunol 1994;153(3):1360-1377.
12. Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287(19):2563-2569.
13. Silverstein J, Maclaren N, Riley W, Spillar R, Radjenovic D, Johnson S. Immunosuppression with azathioprine and prednisone in recent-onset insulin-dependent diabetes mellitus. N Engl J Med 1988;319(10):599-604.
14. Carel JC, Boitard C, Eisenbarth G, Bach JF, Bougneres PF. Cyclosporine delays but does not prevent clinical onset in glucose intolerant pre-type 1 diabetic children. J Autoimmun 1996;9(6):739-745.
15. Weber CJ, Hagler MK, Chryssochoos JT, Kapp JA, Korbutt GS, Rajotte RV, Linsley PS. CTLA4-Ig prolongs survival of microencapsulated neonatal porcine islet xenografts in diabetic NOD mice. Cell Transplant 1997;6(5):505-508.
16. Baeder WL, Sredy J, Sehgal SN, Chang JY, Adams LM. Rapamycin prevents the onset of insulin-dependent diabetes mellitus (IDDM) in NOD mice. Clin Exp Immunol 1992;89(2):174-178.
17. Hao L, Chan SM, Lafferty KJ. Mycophenolate mofetil can prevent the development of diabetes in BB rats. Ann NY Acad Sci 1993;696:328-332.
18. Chatenoud L. The use of monoclonal antibodies to restore self-tolerance in established autoimmunity. Endocrinol Metab Clin North Am 2002;31(2):457-475, (ix).
19. Herold KC, Hagopian W, Auger JA, Poumian-Ruiz E, Taylor L, Donaldson D, Gitelman SE, Harlan DM, Xu D, Zivin RA, Bluestone JA. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346(22):1692-1698.
20. Ludvigsson J, Heding L, Lieden G, Mamer B, Lernmark A. Plasmapheresis in the initial treatment of insulin-dependent diabetes mellitus in children. Br Med J (Clin Res Ed) 1983;286(6360):176-178.
21. Colagiuri S, Leong GM, Thayer Z, Antony G, Dwyer JM, Kidson W, Wakefield D. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin Exp Rheumatol 1996;14(Suppl 15):S93-597.
22. Zhang YC, Pileggi A, Agarwal A, Molano RD, Powers M, Brusko T, Wasserfall C, Goudy K, Zahr E, Poggioli R, Scott-Jorgensen M, Campbell-Thompson M, Crawford JM, Nick H, Flotte T, Ellis TM, Ricordi C, Inverardi L, Atkinson MA. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice. Diabetes 2003;52(3):708-716.
23. Bertera S, Alexander A, Giannoukakis N, Robbins PD, Trucco M. Immunology of type 1 diabetes. Intervention and prevention strategies. Endocrinol Metab Clin North Am 1999;28(4):841-864.
24. Lin-Su K, Kukreja A, Maclaren NK. Diabetes vaccines: A future to be realized. Diabetes Technol Ther 2001;3(3):451-461.
25. Haist RE, Campbell J, Best CH. The prevention of diabetes. N Eng J Med 1940;223:607-615.
26. Polanski M, Melican NS, Zhang J, Weiner HL. Oral administration of the immunodominant B-chain of insulin reduces diabetes in a cotransfer model of diabetes in the NOD mouse and is associated with a switch from Thl to Th2 cytokines. J Autoimmun 1997;10(4):339-346.
27. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993;341(8850):927-928.
28. Fuchtenbusch M, Rabl W, Grassl B, Bachmann W, Standl E, Ziegler AG. Delay of type 1 diabetes in high risk, first degree relatives by parenteral antigen administration: The Schwabing Insulin Prophylaxis Pilot Trial. Diabetologia 1998;41(5):536-541.
29. Diabetes Prevention Trial-Type 1 Diabetes Study Group. Effects of insulin in relatives of patients with type 1 diabetes mellitus. N Engl J Med 2002;346(22):1685-1691.
30. Tian J, Atkinson MA, Clare-Salzler M, Herschenfeld A, Forsthuber T, Lehmann PV, Kaufman DL. Nasal administration of glutamate decarboxylase (GAD65) peptides induces Th2 responses and prevents murine insulin-dependent diabetes. J Exp Med 1996;183(4):1561-1567.
31. Jones DB, Hunter NR, Duff GW. Heat-shock protein 65 as a beta cell antigen of insulin-dependent diabetes. Lancet 1990;336(8715):583-585.
32. Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994;343(8899):704-706.
33. Elias D, Reshef T, Birk OS, van der Zee R, Walker MD, Cohen IR. Vaccination against autoimmune mouse diabetes with a T-cell epitope of the human 65-kDa heat shock protein. Proc Natl Acad Sci USA 1991;88(8):3088-3091.
34. Raz I, Elias D, Avron A, Tamir M, Metzger M, Cohen IR. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): A randomised, double-blind, phase II trial. Lancet 2001;358(9295):1749-1753.
35. Karjalainen J, Martin JM, Knip M, Ilonen J, Robinson BH E, Akerblom HK, Dosch HM. A bovine albumin peptide as a possible trigger of insulin-dependent diabetes mellitus. N Engl J Med 1992;327(5):302-307.
36. Knip M, Akerblom HK. Environmental factors in the pathogenesis of type 1 diabetes mellitus. Exp Clin Endocrinol Diabetes 1999;107 (Suppl 3):S93-S100.
37. Hamalainen AM, Ronkainen MS, Akerblom HK, Knip M. Postnatal elimination of transplacentally acquired disease-associated antibodies in infants born to families with type 1 diabetes. The Finnish TRIGR Study Group. Trial to Reduce IDDM in the Genetically at Risk. J Clin Endocrinol Metab 2000;85(11):4249-4253.
38. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: Molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996;14:1-27 (Review).
39. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol 2002;24(8):525-551.
40. Reddy S, Karanam M, Robinson E. Prevention of cyclophosphamide-induced accelerated diabetes in the NOD mouse by nicotinamide or a soy protein-based infant formula. Int J Exp Diabetes Res 2001;1(4):299-313.
41. Elliott RB, Chase HP. Prevention or delay of type 1 (insulin-dependent) diabetes mellitus in children using nicotinamide. Diabetologia 1991;34(5):362-365.
42. Lampeter EF, Klinghammer A, Scherbaum WA, Heinze E, Haastert B, Giani G, Kolb H. The Deutsche Nicotinamide Intervention Study: An attempt to prevent type 1 diabetes. DENIS Group. Diabetes 1998;47(6):980-984.